Adaptive Biotechnologies
ADPT
230 hedge funds and large institutions have $4.8B invested in Adaptive Biotechnologies in 2021 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 98 increasing their positions, 60 reducing their positions, and 56 closing their positions.
172% more call options, than puts
Call options by funds: $17.2M | Put options by funds: $6.32M
63% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 60
1.95% more ownership
Funds ownership: 81.73% → 83.68% (+1.9%)
5% more capital invested
Capital invested by funds: $4.58B → $4.8B (+$215M)
7% less funds holding
Funds holding: 248 → 230 (-18)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
32% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 56
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$54.2M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$53.8M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$52.2M |
| 4 |
SM
SB Management
Abu Dhabi,
United Arab Emirates
|
+$48.2M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$37.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$46.3M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$30.4M |
| 3 |
Rockefeller Capital Management
New York
|
-$21.4M |
| 4 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
-$19.8M |
| 5 |
GLA
Great Lakes Advisors
Chicago,
Illinois
|
-$13.4M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VFA
276
Valeo Financial Advisors
Carmel,
Indiana
| – | -$9K | -212 | Closed |
|
|
ME
277
McIlrath & Eck
Arlington,
Washington
| – | -$7K | -185 | Closed |
|
|
GWS
278
Glassman Wealth Services
Vienna,
Virginia
| – | -$4K | -94 | Closed |
|
|
EVM
279
Eaton Vance Management
Boston,
Massachusetts
| – | -$3K | -70 | Closed |
|
|
WAP
280
Wealthcare Advisory Partners
West Chester,
Pennsylvania
| – | -$2K | -45 | Closed |
|
281
AssetMark Inc
Concord,
California
| – | -$2K | -43 | Closed |
|
|
GWM
282
Geneos Wealth Management
Englewood,
Colorado
| – | -$1K | -39 | Closed |
|
|
SOW
283
State of Wyoming
Cheyenne,
Wyoming
| – | -$1K | -15 | Closed |
|
ADPT Hedge Fund Activity: Q2 2021 in Review
230 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q2 2021, worth a combined $4.8B — up 4.7% from $4.58B a quarter earlier.
Sellers outnumbered buyers: 56 funds closed out of ADPT and 38 opened new positions — a net loss of 18 holders — while 60 trimmed existing stakes and 98 added.
The largest buyer was Sumitomo Mitsui Trust Group, adding an estimated $54.2M. The largest seller was JP Morgan Chase, cutting an estimated $46.3M.
- 230 institutional investors held Adaptive Biotechnologies (ADPT) as of Q2 2021, down from 248 in Q1 2021.
- Funds reported $4.8B of Adaptive Biotechnologies stock for Q2 2021, up 4.7% quarter-over-quarter.
- 38 funds opened new Adaptive Biotechnologies positions in Q2 2021 and 56 closed out, a net change of -18 holders.
- The largest Adaptive Biotechnologies buyer in Q2 2021 was Sumitomo Mitsui Trust Group, an estimated $54.2M added.
- The largest Adaptive Biotechnologies seller in Q2 2021 was JP Morgan Chase, an estimated $46.3M sold.
Based on aggregated 13F filings for Q2 2021.